Alaunos Therapeutics, Inc. (TCRT) filings document an early-stage biotechnology issuer with a developing small-molecule program, a legacy TCR-T oncology platform and a public-company capital structure. Form 8-K reports cover ALN1003 preclinical disclosures, material agreements, settlement matters, Nasdaq continued-listing notices, governance changes, director and officer transitions, and modifications to stockholder rights.
Registration statements, annual meeting reports and periodic-report references describe securities offerings, authorized common stock, stockholder voting results, operating and financial results, risk factors, and stockholders' equity used in Nasdaq compliance determinations.
Alaunos Therapeutics, Inc. filed an amendment to its annual report to add Part III information that had been omitted from the original Form 10-K. The amendment details the company’s board and governance structure, executive and director compensation, and security ownership of key stockholders and management.
The filing confirms a four‑member board, led by CEO and chair Holger Weis, and describes committee membership and independence under Nasdaq rules. It also outlines employment and consulting agreements, equity incentive plans, ownership concentrations among major holders, and audit fees paid to Cherry Bekaert LLP, without changing previously reported financial statements.
Alaunos Therapeutics, Inc. reported that Nasdaq notified the company on April 9, 2026 that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2,500,000 in stockholders’ equity to remain listed on the Nasdaq Capital Market. The company’s Form 10-K for the year ended December 31, 2025 reported stockholders’ equity of $2,153,000.
The company also does not currently meet Nasdaq’s alternative continued listing standards of a $35 million market value of listed securities or $500,000 in net income from continuing operations in the required periods. Alaunos has 45 calendar days from the date of the notice, until May 26, 2026, to submit a plan to regain compliance, and Nasdaq may grant up to 180 days from the notice date to evidence compliance if the plan is accepted.
The company intends to submit a compliance plan and is evaluating potential actions to regain compliance. If the plan is not accepted, or if compliance is not regained within any extension, Alaunos would have the right to request a hearing before an independent Nasdaq panel, which would temporarily stay any suspension or delisting. Trading in the company’s securities is expected to continue following this disclosure if made within the required timeframe.
Alaunos Therapeutics, Inc. reports a strategic pivot to an early-stage, oral small‑molecule obesity and metabolic disorders program while warning of severe financial strain. For 2025, the company recorded a net loss of $4.2 million and an accumulated deficit of $924.6 million as of December 31, 2025.
Cash and cash equivalents were about $1.4 million, which management expects will fund operations only into the second quarter of 2026, raising substantial doubt about continuing as a going concern. Stockholders’ equity was $2.2 million, below Nasdaq’s $2.5 million equity requirement, creating renewed delisting risk.
The lead obesity candidate, ALN1003, has shown dose-dependent weight loss and metabolic improvements in diet‑induced obesity mouse models but remains in preclinical, non‑GLP studies with significant scientific, regulatory, financing, and execution risks. The company now has only one full-time employee and relies heavily on consultants, has identified a material weakness in internal control due to limited personnel, and highlights the possibility that failure to fund or advance the program could lead the board to consider dissolution and liquidation.
Alaunos Therapeutics’ shareholders led by Adrian Price filed Amendment No. 4 to their Schedule 13D and proposed a major new financing and governance change. The group reports beneficial ownership of 189,061 shares of common stock, representing 8.6% of the company.
In a letter dated February 24, 2026, Price proposed that HexagonONE Ltd, Alimenta Holding Limited and Krakatau Holding Limited invest $7,000,000 in equity or equity-linked securities via a private placement, with pricing to be negotiated and closing after board approval, documentation and any required Nasdaq shareholder approval. The letter says this transaction, if completed, is expected to result in a change of control.
The shareholders asked the board to meet within five business days to negotiate terms, pressed for the appointment of Gerald Bruce as a director, and stated they may buy additional shares, pursue a tender offer or launch an investor relations campaign if the board does not engage. Amendment No. 4 also corrects and updates the list of reporting persons, their addresses and related powers of attorney.
Alaunos Therapeutics reported positive preclinical proof-of-concept data for ALN1003, its lead oral, non-hormonal small-molecule drug candidate for obesity and related metabolic disorders. In two diet-induced obesity mouse studies, ALN1003 produced dose-related body weight loss, favorable body composition changes, and reduced liver weight compared with untreated controls.
ALN1003-treated mice also showed lower liver injury enzymes (ALT, AST, ALP), improved metabolic biomarkers such as glucose and total cholesterol, and macroscopic signs of reduced liver and white fat accumulation. These non-GLP results will guide further preclinical, formulation, manufacturing, and IND-enabling work. Alaunos reported cash and cash equivalents of about $1.9 million as of September 30, 2025, with its cash runway extending into the second quarter of 2026 and plans to seek additional financing.
Alaunos Therapeutics shareholders led by Adrian Price filed an amended Schedule 13D reporting beneficial ownership of 189,061 common shares, or 8.6% of the company. The group sent a letter proposing a $7,000,000 private placement in equity or equity-linked securities by Hexagon ONE Inc, Alimenta Holding Inc and Krakatau Holding Inc, which is anticipated to result in a change of control if completed.
The investors asked the board to negotiate a term sheet within five business days and reiterated their nomination of Gerald Bruce to the board. They indicated they may buy additional shares in the market, launch a tender offer, or run an investor relations campaign if the board does not engage.
Alaunos Therapeutics, Inc. director Jerman Michael Allen reported receiving 5,406 shares of common stock on 01/12/2026 at $2.89 per share. According to the filing, these shares were issued in lieu of cash board fees, meaning the director took stock as compensation for board service. Following this transaction, he beneficially owns 9,589 shares of Alaunos common stock, held directly.
Alaunos Therapeutics director Robert W. Postma received 5,622 shares of common stock on January 12, 2026, as compensation in lieu of board fees at a price of $2.89 per share. Following this grant, he directly holds 43,872 Alaunos shares. He also reports indirect beneficial ownership of 24 shares through his spouse's IRA and 62,416 shares held by WaterMill Asset Management Corp., where he serves as principal.
Alaunos Therapeutics director Jaime Vieser reported receiving additional company stock as compensation. On January 12, 2026, Vieser acquired 5,839 shares of Alaunos Therapeutics common stock at $2.89 per share, described as shares issued in lieu of board fees. After this transaction, Vieser directly holds 32,338 common shares.
Vieser also reports indirect holdings of Alaunos common stock, including 2,100 shares held by the reporter’s children and 13,503 shares held by Brushwood LLC, an entity for which Vieser is the manager. The filing classifies Vieser as a director and indicates the form is filed by one reporting person.
Alaunos Therapeutics, Inc. reported several corporate and R&D updates. The company terminated, effective immediately, its August 14, 2023 engagement letter with Cantor Fitzgerald & Co. as exclusive financial advisor for potential strategic transactions, with no termination fee owed. The board also adopted Amended and Restated Bylaws that add detailed advance notice and disclosure requirements for stockholder director nominations and other business, give the meeting chair authority to rule on compliance, and update various meeting procedures.
The company highlighted that a stockholder group reporting approximately 8.6% ownership has proposed Gerald W. Bruce as a potential director, which the Corporate Governance and Nominating Committee will evaluate. Alaunos provided an update on its preclinical small-molecule obesity program, noting a lead compound and non-GLP mouse data showing statistically significant, dose-related weight loss and improvements in body composition and metabolic parameters. As of September 30, 2025, cash and cash equivalents were about $1.9 million, providing a cash runway into the first quarter of 2026, and the company plans to seek additional financing by the end of that quarter to continue operations and advance the obesity program.